back to top
Thursday, 10 October, 2024
HomeMedico-LegalJudge orders medical aid to pay for boy's expensive medication

Judge orders medical aid to pay for boy's expensive medication

An Alberton mother has won a significant court battle against her medical aid scheme, forcing it to pay for an expensive drug that her three-year-old son needs to treat a rare inherited genetic disorder.

In GroundUp, Tania Broughton writes that Michaney de Wet’s son, Zachary, was diagnosed with Hunter Syndrome a year ago. She applied twice to Medihelp Medical Scheme to authorise the use of Elaprase, an enzyme replacement therapy, and the only registered treatment for the condition in South Africa. The medical scheme turned her down on both occasions.

In July, her son’s health took a turn for the worse. His specialists noted there was damage to his heart valves and that his liver was enlarging. De Wet launched an urgent application in the Gauteng High Court (Pretoria).

On Friday, Judge Anthony Millar directed Medihelp to authorise and pay for the treatment. It is an interim order, pending the outcome of a complaint De Wet has made to the Council for Medical Schemes (CMS).

De Wet was supported in her application by Rare Diseases of South Africa, which advocates for the interests of people with rare diseases.

In his ruling, Millar noted that Hunter Syndrome affects only one in 100 000 people. It is caused by an enzyme deficiency which, if not treated, results in both bodily and organ damage and developmental difficulties.

“It is incurable. However, Elaprase has shown to be an effective treatment that can slow or even halt the progressive degenerative consequences. There is no other treatment available. Zachary’s specialist medical practitioners have motivated it as being an essential part of his treatment,” said Millar.

In its initial refusal, Medihelp gave various reasons, including that the disease was not registered as a prescribed minimum benefit (PMB), and that De Wet’s plan did not cover “chronic medication” or treatment such as Elaprase.

Subsequently, however, the CMS, in considering a complaint against Polmed in a similar matter, ruled that Hunter Syndrome was a PMB condition.

Based on this, De Wet applied once more to Medihelp, but authorisation was again declined. With Zachary’s condition deteriorating, she could not wait for the adjudication on her case by the CMS because it could take up to two years, she said in her affidavit before the court.

Medihelp opposed the application.

Millar said it conceded, in the light of the Polmed ruling, that Hunter Syndrome was a PMB condition. But in reference to a “nuanced” reading of the Medical Schemes Act and its regulations, it said it was under no obligation to pay for Elaprase because its use was not a “prevailing, predominant public hospital practice”.

It argued that Elaprase was expensive. And that while it may be the prevailing and preferred treatment protocol in the private healthcare sector, the same could not be said for the public healthcare sector.

De Wet, however, put up affidavits from heads of rare disease units at state hospitals to prove its use in several public hospitals, including Charlotte Maxeke and the Red Cross Children’s Hospital.

Medihelp, using terminology in the regulations, then argued that it was not used “prevalently”. Millar said this was not surprising, given that the condition was so rare.

“What is apparent is that the use of Elaprase is the only available treatment for MPS II in both the public and private sector, that MPS II is a PMB condition and is being prescribed in both private and public hospitals,” he said. “It is apparent that the deterioration of Zachary’s condition means that if he does not get the treatment, his life and quality of life will be irreparably adversely affected.”

He ruled that pending the outcome of the CMS inquiry, Medihelp must authorise and pay for Zachary to receive all treatment he requires, including Elaprase, within 30 days.

2022-08-26_-_judgment_-_de_wet__another_v_medihelp__another_2022-010668_millar_j

GroundUp article – Mom wins court battle against medical scheme (Creative Commons Licence)

 

See more from MedicalBrief archives:

 

Ill child’s parents sue medical aid over drug for rare disease

 

Med schemes not delivering value for money, say members

 

SA's medical aids rated in customer satisfaction index

 

 

MedicalBrief — our free weekly e-newsletter

We'd appreciate as much information as possible, however only an email address is required.